[go: up one dir, main page]

GB202404661D0 - Antisense oligoncleotides for the treatment of liver disease - Google Patents

Antisense oligoncleotides for the treatment of liver disease

Info

Publication number
GB202404661D0
GB202404661D0 GBGB2404661.7A GB202404661A GB202404661D0 GB 202404661 D0 GB202404661 D0 GB 202404661D0 GB 202404661 A GB202404661 A GB 202404661A GB 202404661 D0 GB202404661 D0 GB 202404661D0
Authority
GB
United Kingdom
Prior art keywords
treatment
liver disease
oligoncleotides
antisense
antisense oligoncleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2404661.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProQR Therapeutics II BV
Original Assignee
ProQR Therapeutics II BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics II BV filed Critical ProQR Therapeutics II BV
Priority to GBGB2404661.7A priority Critical patent/GB202404661D0/en
Publication of GB202404661D0 publication Critical patent/GB202404661D0/en
Priority to PCT/EP2025/058808 priority patent/WO2025210011A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2404661.7A 2024-04-02 2024-04-02 Antisense oligoncleotides for the treatment of liver disease Ceased GB202404661D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2404661.7A GB202404661D0 (en) 2024-04-02 2024-04-02 Antisense oligoncleotides for the treatment of liver disease
PCT/EP2025/058808 WO2025210011A1 (en) 2024-04-02 2025-04-01 Antisense oligonucleotides for the treatment of liver disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2404661.7A GB202404661D0 (en) 2024-04-02 2024-04-02 Antisense oligoncleotides for the treatment of liver disease

Publications (1)

Publication Number Publication Date
GB202404661D0 true GB202404661D0 (en) 2024-05-15

Family

ID=91023421

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2404661.7A Ceased GB202404661D0 (en) 2024-04-02 2024-04-02 Antisense oligoncleotides for the treatment of liver disease

Country Status (2)

Country Link
GB (1) GB202404661D0 (en)
WO (1) WO2025210011A1 (en)

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5635412B2 (en) 2007-12-04 2014-12-03 アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Targeted lipid
KR101885383B1 (en) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 Novel nucleic acid prodrugs and methods of use thereof
CN102869774B (en) 2010-02-24 2018-02-09 箭头研究公司 Composition for targeted delivery siRNA
PL2872485T3 (en) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymmetric auxiliary group
CN104661664B (en) 2012-07-13 2020-07-03 波涛生命科学有限公司 Chiral control
US9650627B1 (en) 2012-07-19 2017-05-16 University Of Puerto Rico Site-directed RNA editing
US8859754B2 (en) 2012-07-31 2014-10-14 Ased, Llc Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides
DK2991656T3 (en) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc COMPOSITIONS AND PROCEDURES FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
JP2017532982A (en) 2014-10-17 2017-11-09 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Isotope substitution of SMAD7 antisense oligonucleotide
US10676737B2 (en) 2014-12-17 2020-06-09 Proqr Therapeutics Ii B.V. Targeted RNA editing
WO2017010556A1 (en) 2015-07-14 2017-01-19 学校法人福岡大学 Method for inducing site-specific rna mutations, target editing guide rna used in method, and target rna–target editing guide rna complex
MA43072A (en) 2015-07-22 2018-05-30 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
DE102015012522B3 (en) 2015-09-26 2016-06-02 Eberhard Karls Universität Tübingen Methods and substances for directed RNA editing
KR20180056766A (en) 2015-10-09 2018-05-29 웨이브 라이프 사이언시스 리미티드 Nucleotide compositions and methods thereof
MA43822A (en) 2016-03-13 2018-11-28 Wave Life Sciences Ltd COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITE AND OLIGONUCLEOTIDES
MA45270A (en) 2016-05-04 2017-11-09 Wave Life Sciences Ltd COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
MA45290A (en) 2016-05-04 2019-03-13 Wave Life Sciences Ltd PROCESSES AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS
EP3458464A1 (en) 2016-05-18 2019-03-27 ETH Zurich Stereoselective synthesis of phosphorothioate oligoribonucleotides
WO2017210647A1 (en) 2016-06-03 2017-12-07 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
KR102824513B1 (en) 2016-07-05 2025-06-25 바이오마린 테크놀로지스 비.브이. Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
DK3507366T3 (en) 2016-09-01 2020-11-02 Proqr Therapeutics Ii Bv CHEMICAL MODIFIED, SINGLE STRANDED RNA-MODIFYING OLIGONUCLEOTIDES
MA46905A (en) 2016-11-23 2019-10-02 Wave Life Sciences Ltd COMPOSITIONS AND SYNTHESIS OF PHOSPHORAMIDITES AND OLIGONUCLEOTIDES
WO2018134301A1 (en) 2017-01-19 2018-07-26 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in rna editing
EP3392267A1 (en) * 2017-04-18 2018-10-24 Myr GmbH Therapy of atherosclerosis, primary biliary cirrhosis and nrlp3 inflammasome-associated disease by htcp inhibitors
TW201908483A (en) 2017-06-02 2019-03-01 新加坡商波濤生命科學有限公司 Oligonucleotide compositions and methods of use thereof
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CN120249271A (en) 2017-06-02 2025-07-04 波涛生命科学有限公司 Oligonucleotide compositions and methods of use thereof
EP3642182A4 (en) 2017-06-21 2020-12-09 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND METHODS OF SYNTHESIS
CN111032057A (en) 2017-08-08 2020-04-17 波涛生命科学有限公司 Oligonucleotide compositions and methods thereof
US11608355B2 (en) 2017-09-18 2023-03-21 Wave Life Sciences Ltd. Technologies for oligonucleotide preparation
AU2018345919B2 (en) 2017-10-06 2025-08-21 Oregon Health & Science University Compositions and methods for editing RNA
JP2020537518A (en) 2017-10-12 2020-12-24 ウェーブ ライフ サイエンシーズ リミテッド Oligonucleotide composition and its method
WO2019111957A1 (en) 2017-12-06 2019-06-13 学校法人福岡大学 Oligonucleotides, manufacturing method for same, and target rna site-specific editing method
US20210079393A1 (en) 2018-02-14 2021-03-18 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for rna editing
SG11202009877XA (en) 2018-04-12 2020-11-27 Wave Life Sciences Ltd Oligonucleotide compositions and methods of use thereof
TWI844541B (en) 2018-05-11 2024-06-11 新加坡商波濤生命科學有限公司 Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2020001793A1 (en) 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
JP2022513719A (en) 2018-12-06 2022-02-09 ウェイブ ライフ サイエンシズ リミテッド Oligonucleotide composition and its method
US11479575B2 (en) 2019-01-22 2022-10-25 Korro Bio, Inc. RNA-editing oligonucleotides and uses thereof
EP3914260A4 (en) 2019-01-22 2023-05-17 Korro Bio, Inc. RNA EDITING OLIGONUCLEOTIDES AND THEIR USES
WO2020154342A1 (en) 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
EP3918067A1 (en) 2019-01-28 2021-12-08 ProQR Therapeutics II B.V. Rna-editing oligonucleotides for the treatment of usher syndrome
CN113423385A (en) 2019-02-01 2021-09-21 波涛生命科学有限公司 Oligonucleotide compositions and methods thereof
GB201901873D0 (en) 2019-02-11 2019-04-03 Proqr Therapeutics Ii Bv Antisense oligonucleotides for nucleic acid editing
US20230089442A1 (en) 2019-03-20 2023-03-23 Pachamuthu Kandasamy Technologies useful for oligonucleotide preparation
US20220307019A1 (en) 2019-03-25 2022-09-29 National University Corporation Tokyo Medical And Dental University Double-stranded nucleic acid complex and use thereof
GB201904709D0 (en) 2019-04-03 2019-05-15 Proqr Therapeutics Ii Bv Chemically modified oligonucleotides
CN113677374A (en) 2019-04-08 2021-11-19 国立大学法人东京医科齿科大学 Pharmaceutical composition for the treatment of muscle diseases
KR102851101B1 (en) 2019-04-15 2025-08-27 에디진 테라퓨틱스(베이징) 인크. Methods and compositions for editing RNA
CA3137740A1 (en) 2019-04-25 2020-10-29 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CA3137741A1 (en) 2019-04-25 2020-10-29 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3965780A4 (en) 2019-05-09 2023-10-25 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
JP7776076B2 (en) 2019-06-05 2025-11-26 学校法人福岡大学 Stable target-editing guide RNA incorporating chemically modified nucleic acids
CA3140877A1 (en) 2019-06-13 2020-12-17 Proqr Therapeutics Ii B.V. Antisense rna editing oligonucleotides comprising cytidine analogs
EP3997229A4 (en) 2019-07-12 2024-07-03 Peking University Targeted rna editing by leveraging endogenous adar using engineered rnas
WO2021020550A1 (en) 2019-08-01 2021-02-04 アステラス製薬株式会社 Guide rna for targeted-editing with functional base sequence added thereto
CN114555621B (en) 2019-08-15 2025-10-28 Ionis制药公司 Bond-modified oligomeric compounds and uses thereof
JP7738323B2 (en) 2019-09-27 2025-09-12 学校法人福岡大学 Oligonucleotides and methods for site-specific editing of target RNA
BR112022006207A2 (en) 2019-10-06 2022-07-26 Wave Life Sciences Ltd OLIGONUCLEOTIDE, OLIGONUCLEOTIDE COMPOSITION, PHARMACEUTICAL COMPOSITION, METHOD, METHOD FOR LOWERING THE ACTIVITY, EXPRESSION AND/OR LEVEL OF A TARGET GENE OR ITS GENE PRODUCT IN A CELL, METHOD TO REDUCE FOCUS IN A CELL POPULATION, METHOD TO REDUCE THE LEVEL OF A DIPEPTIDE REPEAT PROTEIN (DPR), METHOD FOR PREFERRED KNOCKDOWN OF AN RNA TRANSCRIPTION, AND METHOD FOR PREPARING AN OLIGONUCLEOTIDE OR COMPOSITION
EP4022059A4 (en) 2019-10-06 2023-11-01 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
EP4069842A1 (en) 2019-12-02 2022-10-12 Shape Therapeutics Inc. Therapeutic editing
WO2021113390A1 (en) 2019-12-02 2021-06-10 Shape Therapeutics Inc. Compositions for treatment of diseases
US20230059753A1 (en) 2019-12-09 2023-02-23 Astellas Pharma Inc. Antisense guide rna with added functional region for editing target rna
EP3838910B1 (en) 2019-12-18 2022-09-28 Freie Universität Berlin Efficient gene delivery tool with a wide therapeutic margin
WO2021130313A1 (en) 2019-12-23 2021-07-01 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for nucleotide deamination in the treatment of stargardt disease
TW202138561A (en) 2019-12-30 2021-10-16 大陸商博雅輯因（北京）生物科技有限公司 Method for treating usher syndrome and the used composition thereof
JP2023509179A (en) 2019-12-30 2023-03-07 北京▲輯▼因医▲療▼科技有限公司 Methods and compositions for treating MPS IH based on LEAPER technology
JP2023515862A (en) 2020-03-01 2023-04-14 ウェイブ ライフ サイエンシズ リミテッド Oligonucleotide composition and method
WO2021182474A1 (en) 2020-03-12 2021-09-16 株式会社Ｆｒｅｓｔ Oligonucleotide and target rna site-specific editing method
US20230242916A1 (en) 2020-04-15 2023-08-03 Edigene Therapeutics (Beijing) Inc. Method and drug for treating hurler syndrome
CA3173012A1 (en) 2020-04-22 2021-10-28 Susan BYRNE Compositions and methods using snrna components
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231692A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150088A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231680A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4149518A4 (en) 2020-05-15 2024-08-21 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of abca4
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
MX2022014606A (en) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Double stranded oligonucleotide compositions and methods relating thereto.
EP4153604A4 (en) 2020-05-22 2024-11-27 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREFOR
EP4158019A1 (en) 2020-05-26 2023-04-05 Shape Therapeutics Inc. Methods and compositions relating to engineered guide systems for adenosine deaminase acting on rna editing
US20230174977A1 (en) 2020-05-26 2023-06-08 Shape Therapeutics Inc. Engineered circular polynucleotides
EP4158024A2 (en) 2020-05-26 2023-04-05 Shape Therapeutics Inc. Compositions and methods for modifying target rnas
US20230183689A1 (en) 2020-05-26 2023-06-15 Shape Therapeutics Inc. Compositions and Methods for Genome Editing
WO2021243023A1 (en) 2020-05-28 2021-12-02 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of serpina1
EP4177345A4 (en) 2020-07-06 2024-06-26 EdiGene Therapeutics (Beijing) Inc. Improved rna editing method
GB202011428D0 (en) 2020-07-23 2020-09-09 Proqr Therapeutics Ii Bv Antisense oligonucleotides for RNA editing
CA3190477A1 (en) 2020-07-30 2022-02-03 Adarx Pharmaceuticals, Inc. Adar dependent editing compositions and methods of use thereof
WO2022078569A1 (en) 2020-10-12 2022-04-21 Eberhard Karls Universität Tübingen Artificial nucleic acids for rna editing
IL302558A (en) 2020-11-08 2023-07-01 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
EP4244358A4 (en) 2020-11-11 2025-08-06 Shape Therapeutics Inc RNA EDITING COMPOSITIONS AND METHODS OF USE
WO2022103839A1 (en) 2020-11-11 2022-05-19 Shape Therapeutics Inc. Rna editing compositions and uses thereof
IL303533A (en) 2020-12-08 2023-08-01 Univ Fukuoka Stable target-editing guide rna to which chemically modified nucleic acid is introduced
EP4291652A4 (en) 2021-02-11 2025-03-19 Ionis Pharmaceuticals, Inc. OLIGOMERIC COMPOUNDS WITH MODIFIED BONDING AND THEIR USES
IL309503A (en) 2021-06-24 2024-02-01 Lilly Co Eli Innovative therapeutic delivery parts and their uses
EP4363572A4 (en) 2021-06-30 2025-04-09 Ionis Pharmaceuticals, Inc. Method for synthesis of linkage modified oligomeric compounds
EP4416287A1 (en) * 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
US20250154504A1 (en) 2022-02-14 2025-05-15 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Also Published As

Publication number Publication date
WO2025210011A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
IL287522A (en) Compositions useful for treatment of pompe disease
EP4298093A4 (en) Analogs for the treatment of disease
GB202404661D0 (en) Antisense oligoncleotides for the treatment of liver disease
AU2024246572A1 (en) Antisense oligonucleotides for the treatment of liver disease
CA3266876A1 (en) Rifabutin analogs for the treatment of disease
GB202502333D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202414347D0 (en) Antisense oligonucleotides for the treatment of liver disease
AU2023390632A1 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202318087D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202304438D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202418028D0 (en) Antisense oligonucleotides for the treatment of fatty liver disease
GB202405813D0 (en) Antisense oligonucleotides for the treatment of fatty liver disease
CA3286425A1 (en) Antisense oligonucleotides for the treatment of liver disease
GB202502170D0 (en) Antisense oligonucleotides for the treatment of disease
GB202302480D0 (en) shRNA for the treatment of disease
HK40122913A (en) Rifabutin analogs for the treatment of disease
GB202502332D0 (en) Antisense oligonucleotides for the treatment of liver cancer
GB202502189D0 (en) Antisense oligonucleotides for the treatment of liver cancer
GB202503453D0 (en) Compounds for the treatment of skin diseases
GB202403324D0 (en) Compounds for the treatment of skin diseases
GB202316851D0 (en) Antisense oligonucleotides for the treatment of moyamoya disease
GB202508597D0 (en) Compounds for the treatment of cancer
GB202306756D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202218585D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
IL319679A (en) Antisense oligonucleotides for the treatment of canavan disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)